- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Corticobasal degeneration.
Displaying page 1 of 1.
EudraCT Number: 2022-002988-30 | Sponsor Protocol Number: PROFIL-2088-SIM-0032-I | Start Date*: 2023-04-19 | |||||||||||
Sponsor Name:Klinikum rechts der Isar der Technischen Universität München | |||||||||||||
Full Title: Double-blind, randomised, prospective, placebo controlled parallel group phase II study to investigate the effect of glycerol phenylbutyrate (GPB) on neurofilament light chain (NfL) levels in patie... | |||||||||||||
Medical condition: Corticobasal Syndrome (CBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005915-13 | Sponsor Protocol Number: TRx-014-002 | Start Date*: 2006-07-12 | |||||||||||
Sponsor Name:TauRx Therapeutics PTE Ltd | |||||||||||||
Full Title: An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes | |||||||||||||
Medical condition: Frontotemporal Dementia and related syndromes Prevention and reversal of tau protein aggregation is a novel approach to the treatment of patients with FTD and related syndromes and has the potent... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003473-94 | Sponsor Protocol Number: UCL-2016-121 | Start Date*: 2019-05-20 |
Sponsor Name:Cliniques Universitaires Saint-Luc | ||
Full Title: Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms. | ||
Medical condition: Alzheimer’s disease (AD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005539-10 | Sponsor Protocol Number: MRZ60201_3090_1 | Start Date*: 2014-04-29 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two... | |||||||||||||
Medical condition: Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002227-13 | Sponsor Protocol Number: ACP-103-045 | Start Date*: 2018-02-04 | ||||||||||||||||
Sponsor Name:ACADIA Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis | ||||||||||||||||||
Medical condition: Hallucinations and Delusions Associated With Dementia-related Psychosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) SK (Prematurely Ended) BG (Completed) ES (Prematurely Ended) PL (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003536-36 | Sponsor Protocol Number: ACP-103-046 | Start Date*: 2018-09-03 | |||||||||||
Sponsor Name:ACADIA Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerativ... | |||||||||||||
Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003159-12 | Sponsor Protocol Number: J4B-MC-OKAA | Start Date*: 2021-12-24 | |||||||||||
Sponsor Name:Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM) | |||||||||||||
Medical condition: Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000422-38 | Sponsor Protocol Number: PET_imaging_of_Tau | Start Date*: 2014-09-19 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Skåne University Hospital, Region Skåne | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnost... | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000094-36 | Sponsor Protocol Number: BioFINDER_2 | Start Date*: 2017-03-31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Skåne University Hospital | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and mild cogni... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
